MTOR and breast cancer: Thirty-five percent of patients with breast cancer with an alteration in the PI3K/AKT/mTOR pathway who were treated with various therapies that inhibited the PI3K/AKT/mTOR pathway in the SAFIR01 study had an objective response or PFS that lasted longer than 16 weeks.16 The difference in terms of efficacy observed in SAFIR01 might be related to the 16-week threshold used for prolonged disease stabilization—instead of the 6 months in our study—and that various drugs used sometimes in combination, including direct PI3K inhibitors in SAFIR01.